Hepatic Insufficiency Drug Development - Pipeline Analysis 2018 - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “2018 Hepatic Insufficiency Drug Development- Pipeline Analysis Report” report has been added to ResearchAndMarkets.com’s offering.

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered

1 Hepatic Insufficiency Pipeline Analysis

2 Hepatic Insufficiency - Company Wise Pipeline Analysis

3 Hepatic Insufficiency R&D Pipeline Snapshots

4 Recent Developments in Hepatic Insufficiency Pipeline

5 Appendix

Companies Featured

Avexegen Therapeutics BioLineRx Cell2B Glycosyn LLC HepaRegeniX GmbH Infant Bacterial Therapeutics Leadiant Biosciences Martin Pharmaceuticals Mina Therapeutics Novartis AG PledPharma AB ProMetic Life Sciences Promethera Biosciences Proterris Inc Steminent Biotherapeutics Inc Therapure Biopharma Unicyte AG Versantis AG Vital Therapies Inc Xenexus Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/m24rcn/hepatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005485/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 09:34 AM/DISC: 07/12/2018 09:34 AM


Update hourly